NCT01472003View on ClinicalTrials.gov

An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Advanced Solid Tumors
Interventions
DRUG

ABT-806

ABT-806 will be administered by intravenous infusion.

DRUG

ABT-806i

ABT-806i will be administered by intravenous infusion.

Trial Locations (2)

3084

Site Reference ID/Investigator# 52203, Heidelberg

4029

Site Reference ID/Investigator# 58242, Herston

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01472003 - An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types | Biotech Hunter | Biotech Hunter